Ebpay生命医药出版社

Ebpay生命

102494

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.3 Breast Cancer (Dove Med Press)
  • 3.4 Clin Epidemiol
  • 2.5 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.5 Clin Interv Aging
  • 4.7 Drug Des Dev Ther
  • 2.7 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.5 Int J Women's Health
  • 2.5 Neuropsych Dis Treat
  • 2.7 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.3 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 2.8 Diabet Metab Synd Ob
  • 2.8 Psychol Res Behav Ma
  • 3.0 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.7 Risk Manag Healthc Policy
  • 4.2 J Inflamm Res
  • 2.1 Int J Gen Med
  • 4.2 J Hepatocell Carcinoma
  • 3.7 J Asthma Allergy
  • 1.9 Clin Cosmet Investig Dermatol
  • 2.7 J Multidiscip Healthc



更多详情 >>





已发表论文

免疫检查点抑制剂治疗肝细胞癌患者的脾脏体积变化与生存结局:一项回顾性分析

 

Authors Fu X, Jiang S, Li Y, Guo Y, Gong B, Lou J, Li Y, Wang S, Sun Y, Ren Y, Chen Q , Yang L

Received 17 March 2025

Accepted for publication 24 May 2025

Published 30 May 2025 Volume 2025:12 Pages 1069—1082

DOI http://doi.org/10.2147/JHC.S524483

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Mohamed Shaker

Xiaona Fu,1– 3,* Shanshan Jiang,1– 3,* Yi Li,1– 3,* Yusheng Guo,1– 3 Bingxin Gong,1– 3 Jie Lou,1– 3 Yanlin Li,4 Sichen Wang,5 Yuxin Sun,1– 3 Yi Ren,1– 3 Quan Chen,1– 3 Lian Yang1– 3 

1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 2Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, 430022, People’s Republic of China; 3Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China; 4Department of Radiology, the First People’s Hospital of Jiangxia District, Wuhan, 430200, People’s Republic of China; 5School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, Harbin, 150001, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Quan Chen, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China, Email chenquan1230@126.com Lian Yang, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China, Email yanglian@hust.edu.cn

Purpose: The spleen serves as an important immune organ which influences the anti-tumor immune response by modulating the immune microenvironment. This study investigated the prognostic impact of spleen volume (SV) on the survival in hepatocellular carcinoma (HCC) patients receiving immune checkpoint inhibitors (ICIs).
Patients and Methods: This retrospective study included 224 HCC patients treated with ICIs, categorized into Higher and Lower SV groups by median SV and further into SV increased and Non-SV increased groups based on changes in SV at 3 months after ICIs. Kaplan-Meier curves and Cox regression models were used to evaluate the influence of SV and clinical indicators on progression-free survival (PFS) and overall survival (OS). Independent prognostic factors identified via multivariate analysis were incorporated into nomograms, with their accuracy assessed using concordance index (C-index), time-dependent receiver operating characteristic (ROC) and calibration curves. Restricted cubic spline (RCS) analysis was conducted to assess the relationship between baseline SV and survival.
Results: The Higher SV and SV increased groups demonstrated shorter PFS and OS compared to the Lower SV and Non-SV increased groups, respectively. These results were consistent with different regimens in the Child A. The C-index of nomogram for PFS were 0.700 (0.678– 0.721) and OS 0.733(0.709– 0.757). The ROC and calibration curves confirmed robust discrimination and predictive accuracy of models. RCS analysis revealed a nonlinear association between baseline SV and survival risk, providing a more comprehensive overview of SV in relation to survival in HCC patients treated with ICIs.
Conclusion: The baseline SV and its relative change at three months after treatment are expected to become routine imaging makers for predicting survival in HCC patients receiving ICIs, which consequently contributes to their clinical management.

Keywords: spleen volume, hepatocellular carcinoma, immune checkpoint inhibitors, survival, nomogram

Download Article[PDF]